ALK and non-small cell lung carcinoma: There were 171 patients with ALK‐positive advanced NSCLC admitted to our department from 2011 to 2019, among which nine lacked complete case information, 11 were lost to follow‐up, nine were not administered crizotinib, and 14 patients received crizotinib treatment without disease progression.